Tag: PRRT
News and Notes for the Carcinoid and Neuroendocrine Tumor Community, March 2016
Breaking News from Advanced Accelerator Applications (AAA) about PRRT Treatment— Advanced Accelerator Applications announced on March 23 that the company has initiated an expanded access program (EAP) in the United States for the investigational…
READ MORENeuroendocrine Tumors to Be Focus of Presentations and Posters at ASCO Gastrointestinal Cancers Symposium
Presentations on recent advances in the treatment of neuroendocrine tumors (NETs) and new findings from the NETTER-1 clinical study on PRRT with Lutathera along with posters on a wide variety of subjects about NETs will be part of the program during the…
READ MORE10 Highlights of the Year 2015 for the Carcinoid and Neuroendocrine Tumor Community
As we begin a new year, the Carcinoid Cancer Foundation looks back on the highlights of 2015 and to a future that we hope will bring greater awareness of carcinoid and neuroendocrine cancers, earlier diagnosis for patients, new treatment options, and …
READ MORENeuroendocrine Tumors Focus of Upcoming Issue of Hematology/Oncology Clinics
Neuroendocrine Tumors will be featured in the February 2016 issue of Hematology/Oncology Clinics. Dr. Jennifer Chan and Dr. Matthew Kulke, both from Dana-Farber Cancer Institute in Boston, Massachusetts are Editors of the issue, published by Elsevier.…
READ MORE10 Highlights for the Carcinoid and Neuroendocrine Tumor Community
- PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society
DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment
The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…
READ MORE9 More News Items for the Carcinoid and Neuroendocrine Cancer Community
Carcinoid/neuroendocrine cancer specialist Dr. Eric Liu will be joining the Rocky Mountain Cancer Centers in Denver, Colorado, effective June 1, 2015. He and medical oncologist Dr. Allen Cohn, also from Rocky Mountain Cancer Centers, will head up …
READ MORE3rd Theranostics World Congress Offers Free Patient Program on March 14
Johns Hopkins University in Baltimore, Maryland will be the site of the 3rd Theranostics World Congress on Ga-68 & PRRT from March 12-14, 2015. Co-sponsored by the Society of Nuclear Medicine and Molecular Imaging and Johns Hopkins Medicine, the…
READ MOREFirst Northeastern Facility Offers Gallium-68 DOTATOC PET/CT Imaging for Carcinoid and Neuroendocrine Cancer Patients
When Brian Hakimian had the 68Gallium DOTATOC PET/CT scan at the Icahn School of Medicine, Mount Sinai in New York City on January 14, 2015, he became the first carcinoid patient to undergo this novel imaging test at a northeastern facility. Now in clinical…
READ MORE10 Highlights of the Year 2014 for the Carcinoid and Neuroendocrine Tumor Community
As the Carcinoid Cancer Foundation looks back on the year 2014, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…
READ MORE